199 related articles for article (PubMed ID: 31412428)
21. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
[TBL] [Abstract][Full Text] [Related]
22. Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: A prospective multicentre cohort study.
Reijnen C; van der Putten LJM; Bulten J; Snijders MPLM; Küsters-Vandevelde HVN; Sweegers S; Vos MC; van der Wurff AAM; Ligtenberg MJL; Massuger LFAG; Eijkelenboom A; Pijnenborg JMA
Int J Cancer; 2020 May; 146(9):2628-2635. PubMed ID: 31523803
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathology of endometrial carcinoma.
Matias-Guiu X; Prat J
Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
[TBL] [Abstract][Full Text] [Related]
24. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
[TBL] [Abstract][Full Text] [Related]
25. TP53 mutations in endometrial cancers: relation to PTEN gene defects.
Janiec-Jankowska A; Konopka B; Goluda C; Najmoła U
Int J Gynecol Cancer; 2010 Feb; 20(2):196-202. PubMed ID: 20169661
[TBL] [Abstract][Full Text] [Related]
26. The genetic landscape of endometrial clear cell carcinomas.
DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
Li L; Yue P; Song Q; Yen TT; Asaka S; Wang TL; Beavis AL; Fader AN; Jiao Y; Yuan G; Shih IM; Song Y
J Pathol; 2021 Jan; 253(1):119-128. PubMed ID: 33016334
[TBL] [Abstract][Full Text] [Related]
28. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
Macwhinnie N; Monaghan H
Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
30. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
[TBL] [Abstract][Full Text] [Related]
31. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study.
Mayo-de-Las-Casas C; Velasco A; Sanchez D; Martínez-Bueno A; Garzón-Ibáñez M; Gatius S; Ruiz-Miró M; Gonzalez-Tallada X; Llordella I; Tresserra F; Rodríguez S; Aldeguer E; Roman-Canal B; Bertran-Alamillo J; García-Peláez B; Rosell R; Molina-Vila MA; Matias-Guiu X
Int J Cancer; 2020 Jul; 147(1):277-284. PubMed ID: 31953839
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
33. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
34. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
35. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
Russo M; Newell JM; Budurlean L; Houser KR; Sheldon K; Kesterson J; Phaeton R; Hossler C; Rosenberg J; DeGraff D; Shuman L; Broach JR; Warrick JI
Cancer; 2020 Jun; 126(12):2775-2783. PubMed ID: 32187665
[TBL] [Abstract][Full Text] [Related]
36. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic mutations in histologically normal endometrium: the new normal?
Lac V; Nazeran TM; Tessier-Cloutier B; Aguirre-Hernandez R; Albert A; Lum A; Khattra J; Praetorius T; Mason M; Chiu D; Köbel M; Yong PJ; Gilks BC; Anglesio MS; Huntsman DG
J Pathol; 2019 Oct; 249(2):173-181. PubMed ID: 31187483
[TBL] [Abstract][Full Text] [Related]
38. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
39. The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma.
Xiong J; He M; Hansen K; Jackson CL; Breese V; Quddus MR; Sung CJ; Lomme MM; Lawrence WD
Gynecol Oncol; 2016 Jul; 142(1):163-168. PubMed ID: 27154241
[TBL] [Abstract][Full Text] [Related]
40. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse Clinical Outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]